Pomalidomide-d5

Modify Date: 2024-01-08 14:00:08

Pomalidomide-d5 structure	Common Name	Pomalidomide-d5
	CAS Number	1377838-49-7	Molecular Weight	278.27
	Density	1.6±0.1 g/cm3	Boiling Point	582.9±45.0 °C at 760 mmHg
	Molecular Formula	C₁₃H₆D₅N₃O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	306.3±28.7 °C

Use of Pomalidomide-d5

Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

Name	Pomalidomide-d5
Synonym	More Synonyms

Description	Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> PROTAC >> Ligand for E3 Ligase
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. [3]. Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. [4]. Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. [5]. Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. [6]. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. [7]. Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). Gen Comp Endocrinol. 2016 Mar 1;228:1-8.

Density	1.6±0.1 g/cm3
Boiling Point	582.9±45.0 °C at 760 mmHg
Molecular Formula	C₁₃H₆D₅N₃O₄
Molecular Weight	278.27
Flash Point	306.3±28.7 °C
Exact Mass	278.106354
LogP	-0.74
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.691

4-Amino-2-[2,6-dioxo(3,4,4,5,5-2H5)-3-piperidinyl]-1H-isoindole-1,3(2H)-dione

1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl-3,4,4,5,5-d5)-

Pomalidomide-d5

Use of Pomalidomide-d5

Names

Pomalidomide-d5 Biological Activity

Chemical & Physical Properties

Synonyms